Reconstructive Surgery in India and UAE | Complete Patient Guide

• Confirmed diagnosis of invasive breast carcinoma (ductal, lobular, or mixed) or high-grade ductal carcinoma in situ (DCIS) requiring wide local excision or mastectomy

• Patients for whom standard breast-conserving surgery (BCS) alone would yield an unacceptable cosmetic result due to tumour-to-breast volume ratio >20%

• Mastectomy candidates (unilateral or bilateral prophylactic) seeking immediate or delayed reconstruction, including BRCA1/BRCA2 mutation carriers undergoing risk-reduction surgery

• Patients with prior breast surgery or radiation who have residual deformity and wish corrective oncoplastic revision

• Required pre-operative diagnostics: bilateral digital mammography, breast MRI (preferred for lobular histology or dense breast tissue), contrast-enhanced CT of chest/abdomen/pelvis or PET-CT (18F-FDG) for staging, core-needle biopsy with receptor profiling (ER, PR, HER2, Ki-67), full blood count, coagulation screen, LFTs, renal function, ECG, and anaesthetic fitness assessment (ASA classification)

• For flap-based reconstruction: CT angiography of the donor site (e.g., DIEP flap — perforator mapping of deep inferior epigastric vessels; SGAP/IGAP for gluteal flaps; latissimus dorsi perforator mapping)

• Relative contraindications: active uncontrolled systemic infection, severe cardiopulmonary disease precluding general anaesthesia (ASA IV–V), active anticoagulation not bridgeable, collagen vascular disease with micro-vascular complications (relative for free-flap procedures)

• Absolute contraindications to implant-based reconstruction: planned post-mastectomy radiotherapy (PMRT) to the reconstruction site where the surgeon and MDT consider implant exposure risk unacceptable; in such cases autologous reconstruction is preferred

• Oncological contraindication: inflammatory breast cancer (T4d) is generally a contraindication to immediate reconstruction pending neoadjuvant chemotherapy response assessment

Oncoplastic reconstructive techniques are stratified into two broad categories—volume displacement and volume replacement—each subdivided by complexity level and donor-site involvement.

**Level I & II Volume Displacement (Breast-Conserving Oncoplasty)**

Level I techniques (suitable for resections <20% volume) use local glandular re-arrangement and skin closure without formal flap design. Level II techniques address resections of 20–50% volume using pedicled glandular flaps: the round-block (Benelli periareolar) mastopexy, the vertical scar (Lassus/Lejour) reduction pattern, the inverted-T (Wise pattern) reduction mammaplasty oncoplasty, and the lateral or medial glandular rotation flap. These are performed entirely within the breast envelope and typically require a simultaneous contralateral symmetrisation procedure (reduction or mastopexy) for optimal aesthetic balance.

**Volume Replacement — Pedicled Flaps**

When local tissue is insufficient, pedicled flaps import vascularised tissue while maintaining the donor-site blood supply. The latissimus dorsi (LD) myocutaneous flap—either full muscle or the muscle-sparing thoracodorsal artery perforator (TAP) flap variant—is the workhorse for partial or total breast reconstruction, often combined with a silicone implant for volume. The pedicled TRAM (transverse rectus abdominis myocutaneous) flap is now largely superseded by free-flap alternatives due to higher donor-site morbidity.

**Volume Replacement — Microsurgical Free Flaps (Gold Standard for Autologous Mastectomy Reconstruction)**

Free-flap reconstruction requires microsurgical anastomosis of donor vessels to recipient vessels (typically the internal mammary artery and vein). Key options include:

• **DIEP flap** (deep inferior epigastric perforator): The current gold standard; harvests abdominal skin and fat on perforating vessels without sacrificing the rectus abdominis muscle, minimising donor-site morbidity and preserving core strength.

• **MS-TRAM** (muscle-sparing TRAM): Preserves most of the rectus muscle while providing reliable vascularity.

• **SGAP / IGAP flap** (superior/inferior gluteal artery perforator): Used when abdominal tissue is insufficient or previously scarred.

• **PAP flap** (profunda artery perforator): Harvests inner-thigh tissue; growing in popularity for its concealed scar.

• **TUG flap** (transverse upper gracilis): Offers modest volume with acceptable donor scar.

**Implant-Based Reconstruction**

Immediate implant-based reconstruction (IBR) has been transformed by the prepectoral technique, in which an anatomical cohesive gel implant is placed entirely anterior to the pectoralis major muscle, supported by an ADM sling (e.g., Braxon, Strattice, Surgimend). This avoids animation deformity (a known issue with subpectoral placement) and reduces post-operative pain. Tissue expander-to-implant two-stage reconstruction remains appropriate when skin envelope quality is compromised. All implants used in GAF Healthcare partner hospitals are CE-marked and FDA-cleared devices from established manufacturers (Allergan Natrelle, Mentor, Motiva).

**Nipple-Areola Complex (NAC) Reconstruction & Preservation**

Nipple-sparing mastectomy (NSM) is oncologically appropriate for tumours >2 cm from the nipple, with negative retroareolar frozen section; it is now routinely offered in high-volume centres. Where NAC sacrifice is necessary, delayed NAC reconstruction uses local flap techniques (C-V flap, skate flap, star flap) combined with medical tattooing for areola pigmentation.

**Technology Integration**

• Intraoperative fluorescence angiography (SPY Elite / Stryker SPY-PHI) for real-time perfusion mapping to predict and prevent mastectomy skin flap necrosis and free-flap compromise.

• Intraoperative pathology (frozen section / MarginProbe radiofrequency spectroscopy) to confirm tumour-free margins before wound closure.

• 3D surface imaging (Vectra 3D) for pre-operative simulation and post-operative outcome measurement.

• Robot-assisted harvest of the LD flap (da Vinci) is available at select partner hospitals, reducing the axillary/back incision and post-operative donor-site pain.

• Fat grafting (lipofilling/Coleman technique): Used as an adjunct for contour refinement, soft-tissue coverage of implant rippling, and treatment of radiation-damaged tissue; typically performed as a day-procedure 3–6 months after the primary reconstruction.

**Phase 1 — Pre-Travel Preparation (4–8 weeks before departure)**

GAF Healthcare's oncology case managers collect all existing pathology reports, imaging (DICOM files), surgical records, and receptor profiles and route them to the designated reconstructive breast surgeon and MDT at the partner hospital. A virtual MDT consultation is conducted via video link within 5–7 business days. The team issues a written surgical plan specifying: technique selected, staging of procedures, implant selection or free-flap design, and planned adjuvant therapy sequencing. The patient receives a pre-operative checklist: medications to pause (anticoagulants, oestrogen-containing contraceptives 4 weeks pre-op, NSAIDs 2 weeks pre-op), nutritional optimisation (iron supplementation if haemoglobin <11 g/dL, protein intake targets), and smoking cessation (minimum 6 weeks before free-flap surgery to reduce vasospasm risk).

**Phase 2 — Arrival & Pre-Operative Work-Up (Days 1–3)**

On arrival, the patient is met by a GAF Healthcare ground coordinator and transferred to hospital accommodation or a partner serviced apartment. Day 1: registration, baseline blood work confirmation, anaesthetic review, and consent process in the patient's preferred language. Day 2: final imaging review (breast MRI correlation, Doppler/CT angiography for flap perforator mapping if not already performed). Day 3: pre-admission nursing assessment, bowel and skin preparation, pre-operative marking with the surgeon in a pre-op clinic session. The contralateral breast is marked for simultaneous symmetrisation if indicated.

**Phase 3 — Operative Day**

Oncoplastic cases are performed under general anaesthesia. Duration varies by procedure:

• Level II volume displacement: 2.5–4 hours

• LD flap + implant: 3–5 hours

• Nipple-sparing mastectomy + immediate prepectoral IBR (bilateral): 4–6 hours

• Unilateral DIEP free flap: 6–10 hours

• Bilateral DIEP free flap: 8–12 hours

Intraoperative SPY angiography, frozen-section margin confirmation, and microsurgical anastomosis (for free flaps) are performed as standard. The patient is recovered in a dedicated post-anaesthesia care unit (PACU) and transferred to a monitored oncoplastic ward or HDU for free-flap cases.

**Phase 4 — In-Hospital Recovery (Days 1–5 post-op for implant/LD; Days 3–7 for free flap)**

Free-flap patients undergo hourly clinical flap monitoring (colour, capillary refill, Doppler signal) for the first 48 hours; implanted Cook-Swartz Doppler cuffs may be used for continuous surveillance. Drains are managed and removed when output falls below 30 mL/24 hours. Early physiotherapy commences on Day 1 (deep breathing, ankle pumps, gentle shoulder mobilisation). Compression garments are applied per protocol. The surgical team reviews wound healing daily. Pathology report (final margins, nodal status) is discussed with the patient typically on Day 3–4.

**Phase 5 — Post-Discharge, In-Country Recovery (Weeks 1–5/6)**

Patients are discharged to a GAF Healthcare partner recovery apartment with nursing or physiotherapy home-visit support. Follow-up clinic visits occur at Day 7 (wound check, drain removal if still in situ), Day 14 (scar assessment, introduction of silicone sheeting), and Week 4–5 (final pre-flight clinical assessment). Adjuvant systemic therapy planning (chemotherapy, targeted therapy, endocrine therapy) is coordinated with the patient's home oncologist via a structured discharge summary and DICOM imaging package prepared by the hospital's international patient services team.

**Phase 6 — Fit-to-Fly Assessment & Departure**

Fit-to-fly criteria: wounds fully closed with no signs of infection or seroma, drain-free, haemodynamically stable, VTE prophylaxis completed or bridged, and surgeon written clearance. For implant-based reconstruction: typically achievable at 3 weeks. For autologous free-flap reconstruction: typically 5–6 weeks. All patients are discharged with a multi-language medical summary, post-operative care instructions, emergency contact numbers, and a 3-month virtual follow-up schedule via the GAF Healthcare telehealth platform.

**Phase 7 — Long-Term Milestones**

• Month 3: Fat grafting session for contour refinement if required (day procedure)

• Month 4–6: NAC reconstruction (if NAC was sacrificed) using local flap

• Month 8–12: Areola tattooing (medical pigmentation)

• Year 1 and annually: Oncological surveillance mammography/MRI per national guidelines